Treatment of MB07133 Plus Sintilimab in Patients With Hepatocellular Carcinoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

January 18, 2022

Primary Completion Date

July 31, 2024

Study Completion Date

December 31, 2025

Conditions
Safety IssuesEfficacyMTD
Interventions
DRUG

Sintilimab 200mg+MB07133 600mg

"1. Adopting the classic 3+3 scheme design, 3 dose groups, with a cycle of 21 days. On the first day of each cycle, a single infusion of Sintilimab is given, and MB07133 is given for 7 consecutive days after a 2-hour interval between infusion initiation.~2. Sintilimab 200mg+MB07133 1800mg, recruiting 30 subjects,the administration method is as 1."

Trial Locations (1)

Unknown

RECRUITING

The First Hospital of Jilin University, Jilin

All Listed Sponsors
collaborator

The First Hospital of Jilin University

OTHER

lead

Xi'an Xintong Pharmaceutical Research Co.,Ltd.

OTHER